RejuverSen Antibody
Triple-Negative Breast Cancer
Pre-ClinicalIND-enabling, anticipated clinic 2025
Key Facts
Indication
Triple-Negative Breast Cancer
Phase
Pre-Clinical
Status
IND-enabling, anticipated clinic 2025
Company
About Centenara Labs
Centenara Labs is a pioneering longevity-focused biotech that builds and invests in a diversified portfolio of companies targeting geriatric diseases through the lens of aging biology. Its strategy involves de-risking early scientific discoveries by providing a platform of experienced drug developers, business leaders, and capital. With a pipeline built around the hallmarks of aging, the company has progressed two ophthalmology programs into the clinic and is advancing several pre-clinical assets in fibrosis, cancer, and sarcopenia, aiming to create optimal exit scenarios to fund new ventures.
View full company profileTherapeutic Areas
Other Triple-Negative Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CB-839 (Telaglenastat) | Calithera Biosciences | Phase 2 |
| FlowVax BreastCA | Flow Pharma | Pre-clinical |
| Undisclosed circRNA Program | CircNova | Pre-clinical |
| Radiolabeled hTAB004 (Therapeutic) | OncoTAb | Preclinical |
| AI Predictor for TNBC | PathomIQ | Development/Validation |
| TNBC Biomarker/Target Discovery | CogNano | Preclinical (Mouse Studies) |